Evidence map›Paper›PMID 39958117›Full record

ArticleCureus2025

Confirmation of Metformin-Induced Acute Generalized Exanthematous Pustulosis Through a Positive Dechallenge-Rechallenge Test: A Case Report and Review of Cutaneous Manifestations Associated With Metformin.

Haifa A Alfalah, Khalid N Nagshabandi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Haifa A AlfalahDepartment of Internal Medicine and Critical Care, King Abdullah Bin Abdulaziz University Hospital, Riyadh, SAU.
Khalid N NagshabandiDepartment of Dermatology, College of Medicine, King Saud University Medical City, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin, a widely used first-line treatment for type 2 diabetes mellitus (T2DM), is known for its efficacy and safety profile. While gastrointestinal disturbances are the most commonly reported with metformin use, dermatologic reactions, particularly severe ones, are rare and underrecognized. We present a case of a 45-year-old male with a history of atrial fibrillation who developed acute generalized exanthematous pustulosis (AGEP) after initiating metformin for prediabetes.

Indexed as

acute generalized exanthematous pustulosisantidiabeticcutaneous adverse drug reactiondechallenge-rechallenge testexanthematous drug eruptionmetformin

Identifiers

PMID39958117
PMCPMC11825233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.